TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Xeris Pharmaceuticals ( (XERS) ).
On December 1, 2025, Xeris Biopharma Holdings announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for its XP-8121 patent application, marking a significant milestone in the company’s intellectual property strategy. The XP-8121 is a novel formulation designed to address unmet medical needs in hypothyroidism, potentially enhancing Xeris’ market positioning and offering stakeholders promising advancements in drug formulation technology.
The most recent analyst rating on (XERS) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Xeris Pharmaceuticals stock, see the XERS Stock Forecast page.
Spark’s Take on XERS Stock
According to Spark, TipRanks’ AI Analyst, XERS is a Neutral.
Xeris Pharmaceuticals’ overall stock score is driven by its strong earnings call performance, which highlights record revenue growth and strategic plans for future growth. However, significant challenges in financial stability, profitability, and bearish technical indicators weigh heavily on the score.
To see Spark’s full report on XERS stock, click here.
More about Xeris Pharmaceuticals
Xeris Biopharma Holdings, Inc. is a fast-growing biopharmaceutical company focused on developing and commercializing innovative products across various therapies. The company offers three commercially available products: Recorlev® for endogenous Cushing’s syndrome, Gvoke® for severe hypoglycemia, and Keveyis® for primary periodic paralysis. Xeris is also advancing a pipeline of development programs, including XP-8121, a once-weekly subcutaneous injection for hypothyroidism, leveraging its XeriSol® and XeriJect® technology platforms.
Average Trading Volume: 2,360,236
Technical Sentiment Signal: Buy
Current Market Cap: $1.19B
Find detailed analytics on XERS stock on TipRanks’ Stock Analysis page.